Canadian Regulatory and Health Technology Assessment for Malignant Hematology and Oncology Indications Compared With the US Food and Drug Administration Accelerated Approval Program.
other · Level V
Where this comes from
- Record sourced from PubMed, PMID 34379128.
- Also identified by DOI 10.1001/jamanetworkopen.2021.20301 and PMC identifier 8358729.
- Licence recorded as CC BY.
- The licence permits redistribution, so the abstract is shown in full and the full text is available from the publisher.
Abstract
This quality improvement study compares US Food and Drug Administration accelerated approvals with Canadian health and technology assessment approvals and timelines for malignant hematology and oncology treatments.
Medical subject headings
- Antineoplastic Agents
- Drug Approval
- Hematologic Neoplasms
- Practice Guidelines as Topic
- United States Food and Drug Administration